There is significant interest in immunotherapy to treat high-risk smoldering multiple myeloma (SMM), but no available data on the immune status of this particular disease-stage. Such information is important to understand the interplay between immune-surveillance and disease transformation, but also to define if patients with high-risk SMM might benefit from immunotherapy. Here, we have characterized Tlymphocytes (including CD4, CD8, TCRγδ, and Tregs), NK-and dendritic-cells from 31 high-risk SMM patients included in the treatment arm of the Quiredex trial, and with longitudinal peripheral blood samples at baseline, after 3 and 9 cycles of lenalidomide/dexamethasone (LenDex). High-risk SMM patients showed at baseline decreased expression of activation-(CD25/CD28/CD54), Th1-(CD195/IFN-γ/TNF-α/IL-2), and proliferation-related markers (CD119/CD120b) as compared to age-matched healthy individuals. However, LenDex was able to restore the normal expression levels for those markers, and induced a marked shift in T-lymphocytes and NK-cells phenotype. Accordingly, high-risk SMM patients treated with LenDex showed higher numbers of functionally active T-lymphocytes. Altogether, our results indicate that highrisk SMM patients have an impaired immune system that could be re-activated by the immunomodulatory effects of lenalidomide even when combined with low-dose dexamethasone, and support the value of therapeutic immunomodulation to delay the progression to MM.
Introduction
Multiple myeloma (MM) is an incurable plasma cell (PC) malignancy characterized by preceding benign stages termed as monoclonal gammopathy of undetermined significance (MGUS) or smoldering MM (SMM). Interestingly, no major differences have been described for the genetic and phenotypic profiles of clonal PCs during disease evolution from MGUS to SMM and treatment-requiring MM. [1] [2] [3] [4] [5] [6] [7] [8] In contrast, an intrinsic relation between a progressively impaired immune system and disease progression has been suggested 9, 10 and in fact, one of the risk factors that predicts transformation of SMM into treatment-requiring MM is the presence of immune paresis. 11 Accordingly, extensive characterization of bone marrow (BM) and peripheral blood (PB) samples from MGUS and MM patients has revealed that while immune effector cells remain functional in the former, T-lymphocytes and NK-cells from newlydiagnosed and relapsed MM are unable to produce a tumor-specific immune response due to i) cytokine production by clonal PCs (e.g.: transforming growth factor β) 12 , ii) Tcell exhaustion and anergy 13, 14 , or iii) inhibitory signaling through co-expression of PD-1 and PD-L1 in effector and tumor cells, respectively. 15, 16 However, it remains unclear whether the quantitative and functional immune deregulation typically observed in MM is a cause or consequence of the increasing tumor burden. 10 Because immune modulatory drugs (IMiDs) and novel monoclonal antibodies (e.g.: anti-CD38 and anti-SLAMF7) rely on the activity of T-lymphocytes and NK-cells 17 , such impaired immune system may represent a barrier for immunotherapy in active disease but not in preceding SMM, for which immune-therapeutic strategies aiming at preventing disease progression would be effective with the help of functionally active T-lymphocytes and NK-cells. Unfortunately, there is virtually no data on the immune status of patients with SMM nor if it could be therapeutically modulated (e.g.: using IMiDs); such information would be important to further understand the interplay between immune surveillance and disease transformation, as well as to define if patients with SMM might benefit from immune therapeutic strategies.
The interest in SMM has significantly increased in recent years due to both the identification of well-defined patient-subgroups with different risk of progression 11, 18 , and to the demonstration of the potential benefit in time-to-progression (TTP) and overall survival (OS) of treating high-risk SMM patients with lenalidomide plus low-dose dexamethasone. 19 Noteworthy, a recent update of this trial has shown that even though a significant fraction of patients remained with detectable disease after therapy (i.e.:
less than CR), only 14 out of 57 (25%) patients randomized to receive treatment have progressed so far 20 ; hence, it could be hypothesized that in addition to the direct tumor reduction induced by lenalidomide plus dexamethasone (LenDex), other factors such 4 as immune surveillance might play a role in delaying tumor progression. However, this has never been demonstrated. Furthermore, the combination used in the Quiredex trial includes the potential antagonist effects of the immune modulatory lenalidomide vs. the immune suppressive dexamethasone [21] [22] [23] [24] [25] ; accordingly, such potentially antagonist combination may represent a dilemma in the design of clinical trials investigating preemptive therapy in high-risk SMM. 26 Here, we have analyzed the phenotypic profile of T-lymphocytes, NK-cells and dendritic cells (DCs) in high-risk SMM patients enrolled in the Quiredex trial, and compared them against age-matched healthy individuals to determine the immune status in high-risk SMM. Afterwards, we monitored such patients after 3 and 9 cycles of LenDex induction to evaluate the role of T-lymphocyte and NK-cell functionality in delaying disease progression into symptomatic MM. Finally, we compared the immune profile of both cell populations during maintenance with lenalidomide as single-agent to measure the potential antagonist effect of dexamethasone.
Patients and Methods
Study design. In this pre-planned exploratory analysis, we evaluated the immunophenotypic profile of T-lymphocytes and NK-cells on a total of 119 PB samples from 31 of the 57 high-risk SMM patients allocated into the treatment arm of the Quiredex trial, and for which longitudinal samples were available at baseline, after 3 cycles of LenDex, at the end of induction therapy, and during maintenance with lenalidomide at least 3 months after dexamethasone discontinuation (the later analysis being performed in 13 of the 31 patients). The criteria for patient inclusion and the design of the Quiredex trial have been described elsewhere 19 ; briefly, high-risk SMM was defined based on the presence of at least 2 of the 3 following criteria: BM PC infiltration ≥10%; high M-component (IgG≥30g/L or IgA≥20g/L or B-J Protein>1g/24h) 18 ; or ≥95% clonal PCs from total BM PCs plus immune paresis. 11 High-risk SMM patients were treated with an induction phase of 9 four-week cycles of LenDex followed by maintenance with lenalidomide; maintenance therapy was initially given until disease progression, but a protocol amendment limited the total duration of treatment (induction plus maintenance) to 2 years. 19 A total of 10 healthy donors aged over 60 years were also studied and used as normal reference. All control and patient samples were collected after informed consent was given by each individual, according to the local ethical committees and the Helsinki Declaration. Baseline demographic and disease characteristics of high-risk SMM patients are summarized in Table 1 . T-lymphocytes were significantly decreased at the end of induction therapy ( Figure 1A ).
Immunophenotypic protein expression profile (iPEP) of T-lymphocytes
No significant differences were noted for the remaining cell populations including overall DC counts and distribution of DC subsets and tissue macrophages, nor for the relative distribution of the CD4/CD8 and CD56 dim /CD56 bright subsets within total T-lymphocytes and NK-cells, respectively ( Figure 1B ). By contrast, there was a marked shift on the distribution of antigen-related maturation subsets induced by LenDex, and reflected by a significant increase of central memory CD4 (38% vs. 52% vs. 61% at baseline, cycles 3 and 9 of LenDex, respectively; P <.001) and effector memory CD8 (46% vs. 60% vs. 58% at baseline, cycles 3 and 9 of LenDex, respectively; P <.001) Tlymphocytes ( Figure 1C) . Since the accumulation of antigen-experienced Tlymphocytes is typically related to increased activation and proliferation, we then compared the iPEP of T-lymphocytes and NK-cells of all patient' samples longitudinally collected at baseline, and after cycles 3 and 9 of LenDex ( Figure 4) . Accordingly, CD4
and/or CD8 T-lymphocytes showed an increased expression of activation markers such as CD69, CD25, CD28, and CD54, together with an up-regulation of the Th1 related chemokine CCR5 (CD195) and increased cytokine production of IFNγ, TNFα, and IL-2.
An overall analysis on total (CD3 
Discussion
Understanding the biologic and cellular mechanism involved in the transition between benign and malignant MM has become particularly important with the emergence of new diagnostic criteria 29 and potential benefit for early-treatment of SMM patients at higher risk of progression into symptomatic MM. 19 However, while several studies have focused on the genomic characterization of SMM [1] [2] [3] [4] 6, 7, 30 , no research efforts have been made to evaluate the immune system of SMM. 10 Here, we undertook a detailed characterization of high-risk SMM patients' immune status and noted a mild functional impairment as compared to age-matched healthy individuals;
afterwards, we demonstrated that high-risk SMM patients can be effectively immune modulated by lenalidomide and consequently, we also showed that the immune modulatory effects of lenalidomide were not lost when combined with low-dose dexamethasone. These observations suggest that increasing numbers of functionally active immune cells after LenDex may have partially contributed to reduce the risk of transformation of high-risk SMM patients.
Extensive studies in the BM and PB samples from patients with MGUS and symptomatic MM have shown that T-lymphocytes and NK-cells become quantitatively
and functionally altered in the latter stage of the disease [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] , thereby suggesting a relation between an impaired immune system and the transformation of MM.
Conversely, we 41 and others 43 have recently shown that patients in "operational cure" 2.This is thought to explain its dual mechanism of action involving both a direct anti-MM activity (through reduced IRF4 expression) and immune modulation (through boosted IL-2 production by T-lymphocytes). 47, 48 In addition, lenalidomide increases NK-cell responses by lowering its activation threshold through both CD16 and NKG2D. 49 Thus, significant concern exists on the simultaneous use of dexamethasone with IMiDs because it could antagonize the immune-enhancing effect of the latter. Accordingly, it has been shown that dexamethasone abrogates lenalidomide induced T-lymphocyte production of IL-2 and NK-cell production of IFNγ and granzyme B, NK-cell receptor expression, and in vitro NK-cell mediated cytotoxicity. [21] [22] [23] [24] [25] However, contrasting results have also been reported and suggested that in vitro, antigen-dependent activation of NKT cells is greater in the presence of LenDex than with dexamethasone alone. 50 While these findings have obvious clinical implications, it should also be noted that these studies have been mostly performed in vitro, using high-doses of dexamethasone, and in small patient series. In fact, very recent data has shown that PomDex can induce rapid activation of innate and adaptive immunity in heavily pretreated relapsed/refractory patients 51 , which further contributes to the uncertainty about the potential antagonizing effect of dexamethasone in combination with IMiDs.
Here, we had the unique opportunity to study T-lymphocytes and NK-cells from treatment-naïve high-risk SMM patients included in the Quiredex trial and exposed to 9 induction cycles of lenalidomide plus low-dose dexamethasone 19 , to elucidate whether or not the use of corticosteroids may have a detrimental effect on the immune modulatory activity of lenalidomide. Our results, based on longitudinal samples collected at baseline and after cycles 3 and 9 of LenDex, show a significant increase of TCRγδ positive T-lymphocytes at cycle 3 coupled with a decrease of CD4 Tlymphocytes at cycle 9. However, the most notorious differences in cellular distribution were noted for the distribution of T-lymphocyte antigen-related maturation subsets; the fact that CD4 and CD8 T-lymphocytes become enriched in central and effector memory cells after 3 and 9 cycles of LenDex identifies them as not yet terminally differentiated, which makes them promising candidates for anti-tumor response. Furthermore, it was interesting to observe that LenDex was able to restore the expression of those activation-, Th1-and proliferation-related markers that at baseline were found to be down-regulated in both CD4 and CD8 T-lymphocytes of high-risk SMM patients as compared to age-matched healthy individuals. CD56 dim cytotoxic and CD56 bright immune regulatory NK-cells were also found to be significantly activated after therapy. 
